Can-Fite BioPharma Ltd (CANF) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Investors in Can-Fite BioPharma Ltd, particularly those in the United States holding 10% or more of the company’s shares, face potential adverse tax implications under U.S. federal income tax regulations. Being classified as a “United States shareholder” of a “controlled foreign corporation” within the Can-Fite group, these investors could be subjected to mandatory inclusion of certain types of income on their tax returns and compliance with stringent reporting obligations, regardless of actual distributions received. Additionally, individual U.S. shareholders may be ineligible for specific deductions and credits available to corporate shareholders, further compounding their tax burden. Non-compliance risks severe penalties and an open-ended statute of limitations on the relevant tax returns, yet Can-Fite BioPharma offers no assurance of assistance in shareholder determinations or compliance.
Overall, Wall Street has a Moderate Buy consensus rating on CANF stock based on 1 Buy.
To learn more about Can-Fite BioPharma Ltd’s risk factors, click here.
